Cervicovaginal zinc and copper profiles across vaginitis phenotypes and hydrogel assignment: an exploratory pilot study
Effect direction cannot be determined: the transmitted text lacks primary numerical results and clinical outcome data.
| Population | Women with distinct vaginitis phenotypes (BV, VVC, trichomoniasis, non-infectious) and healthy controls |
|---|---|
| Intervention | Zinc-containing hydroxyethyl cellulose (HEC)-based vaginal hydrogel |
| Comparator | No hydrogel or healthy controls (not clearly specified in the provided text) |
| Outcome | Cervicovaginal zinc concentration by vaginitis phenotype; Cervicovaginal copper concentration by vaginitis phenotype; Vulvovaginal symptoms after zinc hydrogel use |
Summary of findings
| Outcome | Effect | 95% CI | Certainty | Clinical relevance | Notes |
|---|---|---|---|---|---|
| Cervicovaginal zinc concentration by vaginitis phenotype | not reported in transmitted text | — | Very low | — | |
| Cervicovaginal copper concentration by vaginitis phenotype | not reported in transmitted text | — | Very low | — | |
| Vulvovaginal symptoms after zinc hydrogel use | not reported in transmitted text | — | Very low | — |
Context
Vaginitis affects a large proportion of women worldwide, with recurrent VVC posing particular management challenges. Zinc and copper at mucosal surfaces may modulate antimicrobial defense and epithelial repair, yet cervicovaginal metal biology is poorly characterized. Mapping Zn and Cu profiles across vaginitis phenotypes could inform adjunct mucosa-targeted strategies.
What the study showed
The full text provided does not contain primary numerical results (means, medians, 95% CIs, p-values, or effect sizes). The Results and Discussion sections were replaced by PMC editorial metadata, making quantitative extraction impossible. No absolute or relative numbers can be stated based on the material received.
How it was done
Exploratory pilot study (non-randomized or observational design, self-classified as pilot). Conducted at the University of Debrecen. Cervicovaginal lavage samples were collected for Zn and Cu quantification. Sample size, study duration, and inclusion/exclusion criteria were not reported in the provided text.
Effect magnitude
No effect size can be calculated or reported: primary numerical data are absent from the received text.
Risk of bias
The transmitted text is structurally incomplete — Results and Discussion sections contain only PMC metadata without clinical or statistical data. Risk-of-bias tools (RoB 2, ROBINS-I) cannot be applied without access to complete methods and results. The study self-identifies as an exploratory pilot, inherently limiting statistical power and generalizability regardless of findings.
What this study does NOT prove
This study does NOT prove clinical efficacy of zinc hydrogel in vaginitis, nor does it establish causality between Zn/Cu concentrations and clinical outcomes. Available data are insufficient for any inference on effect direction or magnitude.
In clinical practice
Without verifiable numerical data, no clinical recommendation can be derived from this study. Clinicians should not modify practice based on this publication until complete results are available and critically appraised.
Limitations
The transmitted text is structurally incomplete — Results and Discussion sections contain only PMC metadata without clinical or statistical data. Risk-of-bias tools (RoB 2, ROBINS-I) cannot be applied without access to complete methods and results. The study self-identifies as an exploratory pilot, inherently limiting statistical power and generalizability regardless of findings.
What is still missing
RCTs with parallel groups, phenotype-stratified adequate samples, and validated clinical outcomes are needed to establish whether cervicovaginal Zn/Cu profiles have diagnostic or therapeutic utility. Dose-response and safety studies of Zn hydrogel in recurrent VVC are a research priority.
Technical appendix
Version history
- 1.0 · 2026-11-03 — Auto-generated under Evidence Standard v1.0